Skip to main content
. 2017 Nov 15;26(146):170066. doi: 10.1183/16000617.0066-2017

TABLE 3.

Currently approved targeted therapies in nonsmall cell lung cancer along with their target

Drug Target Line
Erlotinib EGFR sensitising mutation 1
Gefitinib EGFR sensitising mutation 1
Afatinib EGFR sensitising mutation 1
Osimertinib EGFR T790M mutation 1+
Crizotinib ALK/ROS1 1
Ceritinib ALK 2
Dabrafenib+trametinib BRAF 1

EGFR: epidermal growth factor receptor; ALK: anaplastic lymphoma kinase.